Shionogi, Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- $13.1B
Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 779
- Registration Number
- NCT01651871
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 301
- Registration Number
- NCT01586364
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 180
- Registration Number
- NCT01585558
A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 244
- Registration Number
- NCT01443403
- Locations
- 🇺🇸
Shionogi Research Site, Salt Lake City, Utah, United States
Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 218
- Registration Number
- NCT01240759
- Locations
- 🇺🇸
Juno Research, LLC, Houston, Texas, United States
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 34
- Registration Number
- NCT01154348
- Locations
- 🇺🇸
Dennis Ruff, MD, San Antonio, Texas, United States
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 19
- Registration Number
- NCT01129024
- Locations
- 🇺🇸
Investigator, Seattle, Washington, United States
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 486
- Registration Number
- NCT01126970
Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 72
- Registration Number
- NCT01122030
- Locations
- 🇺🇸
Shionogi Research Site, Salt Lake City, Utah, United States
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 20
- Registration Number
- NCT01054443
- Locations
- 🇺🇸
Investigator, Seattle, Washington, United States
© Copyright 2024. All Rights Reserved by MedPath